What is Bio-Techne's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Bio-Techne year over year?

What is Bio-Techne's gross profit margin?

What guidance did Bio-Techne's management provide for the next earnings period?

What is the market's earnings forecast for Bio-Techne next quarter?

What factors drove the changes in Bio-Techne's revenue and profit?

Did Bio-Techne beat or miss consensus estimates last quarter?

What were the key takeaways from Bio-Techne's earnings call?

- **Core Performance**: Flat Q2 revenue ($295.9M) with 31.1% operating margin (100bps expansion)
- **Growth Verticals**: 47% of revenue from high-growth segments (cell therapy, proteomics, spatial, diagnostics)
- **Key Drivers**: Pharma demand (+low double digits), China/Asia growth (mid-single digits), new product launches
- **Challenges**: Biotech funding lag (~6-9 months), academic market softness
- **Margin Outlook**: Sequential gross margin improvement in H2
- **M&A Focus**: Strategic acquisitions in antibodies, cell therapy, proteomics

**【CEO Summary Section】**
- Q2 organic revenue was flat year-over-year, driven by strong pharma demand offset by soft biotech and academic markets. Key highlights include:
  - Cell therapy (excluding 2 large FDA Fast Track customers) grew 30%, with sequential improvement.
  - Spatial Biology bookings for COMET instrument up 40% QoQ.
  - China and APAC grew mid-single digits, contributing to 3 consecutive quarters of growth.
  - Operating margin expanded 100bps to 31.1%, driven by cost control and strategic investments in growth verticals (cell therapy, proteomics, spatial biology, diagnostics).
  - 4 growth verticals now represent 47% of revenue (vs. 32% in 2020), with upper teens CAGR over 5 years.

**【CFO Financial Commentary】**
- Q2 revenue: $295.9M (flat YoY), with $0.46 EPS (10% YoY growth). Key metrics:
  - Adjusted EBITDA margin: 31.1% (100bps expansion)
  - Gross margin: 68.5% (down 200bps YoY due to product mix)
  - SG&A: 29.6% of revenue (down 240bps YoY)
  - Free cash flow: $82.4M (strong cash generation)
  - Balance sheet: $12.9M cash, <1x leverage
- Growth drivers: pharma demand, China/Asia growth, and new product launches (e.g., Ella ultrasensitive assays,10X pull-through rate)
- Risks: biotech funding lag (~6-9 months), academic market stabilization

**【Q&A Key Highlights】**
- **Growth Outlook**: Mid-single-digit underlying growth (excluding 2 large cell therapy customers). Q4 2026 will lap easier comps.
- **Gross Margin**: Expected sequential improvement in H2 due to product mix recovery.
- **China Strength**: 3Q26 growth driven by CDMO/CRO investment in advanced therapies.
- **AI Impact**: Enabling more complex molecule development, aligning with company's high-quality reagent expertise.
- **M&A Pipeline**: Actively evaluating deals in novel antibodies, cell therapy, proteomics.
- **Wilson Wolf**: 20% owned bioreactor business grew 20% Q2, on track for full acquisition by end-2027.


Bio-Techne Corporation (TECH) Q2 2026 Earnings Call Transcript

**Key Takeaways:**
- **Headwind Warning**: Q2 organic growth will face 400 bps headwind from 2 large cell therapy customers, but FY26 low single-digit guidance maintained.
- **Margin Strength**: 90 bps operating margin expansion in Q1 (29.9%) despite revenue decline, driven by cost control and productivity.
- **China Growth Engine**: 2q growth streak in spatial biology (+low single digits) and ProteinSimple (+mid-single digits), led by China.
- **Biotech Recovery Signs**: Q1 biotech funding +6% MoM, M&A/licensing up. Expect 2-3q lag to revenue.
- **Sustainability Progress**: 40% reduction in Scope 1/2 emissions vs. FY25, 100% renewable energy at Minneapolis site.

**【CEO Summary Section】**
- Q1 organic revenue declined 1% due to clinical stage timing in cell therapy and biotech funding softness, offset by mid-single-digit growth in China and ProteinSimple instruments.
- Adjusted operating margin expanded 90 bps to 29.9%, driven by productivity and cost management.
- Cell therapy headwind from 2 large customers (FDA Fast Track designees) will peak in Q2 (-400 bps YoY) before moderating in H2.
- Encouraging signs of stabilization in biotech funding (M&A, licensing trends) and U.S. academic markets.

**【CFO Financial Commentary】**
- Q1 revenue $286.6M (-1% YoY), adjusted EPS $0.42 (flat YoY). GAAP EPS $0.24 (+14% YoY).
- Excluding cell therapy timing, organic growth +1%. North America down mid-single digits, EMEA/Asia low single-digit growth.
- Adjusted gross margin 70.2% (+60 bps YoY), SG&A 32.1% (flat YoY), R&D 8.2% (flat YoY).
- Operating margin 29.9% (+90 bps YoY), driven by Exosome divestiture and productivity.
- Q2 outlook: organic growth consistent with Q1, despite +400 bps cell therapy headwind.

**【Q&A Highlights】**
- **Cell Therapy Timing**: 2 customers progressing Phase III trials, reducing reagent purchases. Headwind to peak Q2 (-400 bps) before moderating. 2027+ growth outlook unchanged.
- **Biotech Recovery**: Q1 funding +6% MoM, M&A/licensing activity up. Expect 2-3q lag to revenue.
- **China Momentum**: 2q growth streak in spatial biology and ProteinSimple, driven by CRO/CDMO activity.
- **Margin Resilience**: 90 bps margin expansion in Q1 despite headwinds. On track for +100 bps FY26.
- **Segment Performance**: Protein Sciences (-1% YoY), Diagnostics/Spatial (+3% YoY ex Exosome).

Bio-Techne Corporation (TECH) Q1 2026 Earnings Call Transcript

- **Exosome Diagnostics Divestiture**: Expected to close in Q1 2026, freeing up $25.9M in FY2025 revenue.
- **China Tariff Concerns**: Low double-digit growth in Q4 due to pre-tariff buying.
- **Margin Expansion**: 100bps FY2026, driven by cost savings and reduced Exosome exposure.
- **Wilson Wolf Milestones**: EBITDA threshold could accelerate acquisition timeline.
- **Market Uncertainty**: NIH funding and MFN pricing policy risks.


**【Management Opening Remarks】**
- Announced the divestiture of Exosome Diagnostics to MDxHealth, expected to close in Q1 2026, freeing up resources for core growth initiatives.
- Highlighted upcoming industry conference participation and the company's focus on strategic portfolio reshaping.

**【CEO Commentary】**
- Q4 2025 organic revenue growth of 3%, driven by biopharma (high single-digit growth) and cell therapy solutions (20%+ GMP reagent growth).
- Academic revenue decline offset by stable reagent sales, with <1/3 of U.S. academic revenue tied to NIH grants.
- China delivered low double-digit growth, partly due to tariff-related pull-forward, with broader market stabilization expected.
- Wilson Wolf (cell therapy bioreactor) grew 20% FY2025, EBITDA >70%, with potential for earlier acquisition if milestones met.
- Emphasized portfolio resilience (80% consumables) and margin discipline (32% adjusted operating margin).

**【CFO Commentary】**
- Q4 2025 revenue $317M (+3% organic), adjusted EPS $0.53 (+8%), GAAP EPS -$0.11 due to restructuring.
- FY2026 guidance: low single-digit organic growth, 100bps margin expansion via cost savings and Exosome divestiture.
- FY2025 Exosome Diagnostics drag of 200bps on margin, to be resolved post-divestiture.
- Strong cash flow ($98M operating) and share buybacks ($100M in Q4).

**【Q&A Highlights】**
- Tariff and NIH funding uncertainties expected to persist, but pharma instrumentation demand remains strong.
- China growth may moderate after pull-forward effect dissipates.
- M&A pipeline focused on strategic takedowns of 1-2% ownership.
- Divestiture proceeds may be reinvested into core franchises.


Bio-Techne Corporation (TECH) Q4 2025 Earnings Call Transcript

- **Q3 Growth Resilience**: 6% organic revenue growth despite macro uncertainty, driven by pharma (low double-digit) and core reagents (7%).
- **Academic Market Risk**: NIH policy uncertainty flattens academic growth, but 12% of revenue tied to NIH grants limits long-term impact.
- **Tariff Mitigation**: $20M annual tariff impact to be fully offset by Q1 2026 via regional production and pricing adjustments.
- **Cell & Gene Momentum**: Trailing 12-month reagent growth 13%, positioning for clinical pipeline expansion.
- **Instrument Innovation**: Maurice and COMET instruments deliver double-digit growth, leveraging biologics QA/QC and multiomics capabilities.

**【CEO Opening Remarks】**
- Q3 organic revenue growth of 6%, driven by pharma (low double-digit) and core reagents (7%).
- Academic end market impacted by NIH policy uncertainty, leading to flat Q3 performance.
- Tariff mitigation efforts underway, with global production diversification and pricing adjustments to offset $20M annual impact.
- Cell & gene therapy reagents show trailing 12-month growth of 13%, despite quarterly volatility.
- Maurice instrument placements up double-digit, leveraging biologics QA/QC demand.

**【CFO Financial Highlights】**
- Q3 revenue: $316.2M (6% YoY organic), adjusted EPS: $0.56 (16% YoY increase).
- Adjusted operating margin: 34.9% (190bps YoY expansion), driven by cost control and volume leverage.
- Free cash flow: $41.1M, with $112.6M returned to shareholders via dividends and buybacks.
- FY2025 guidance: Q4 organic growth expected to slow to low-single digits due to macro uncertainty, with operating margin temporarily down 100-150bps.

**【Q&A Key Takeaways】**
- Academic market: 12% of revenue, 50% sourced from NIH grants. Severe NIH cuts would have <1% impact on long-term growth.
- China: 9% of revenue, 50/50 split between instruments/consumables. Tariff mitigation via regional manufacturing underway.
- Cell & gene therapy: Trailing 12-month growth 30%, but quarterly volatility persists due to late-stage clinical orders.
- Spatial Biology: COMET instrument double-digit growth, multiomics capabilities driving consumables pull-through.
- Tariff response: $20M annual impact expected, fully mitigated by Q1 2026 via production diversification and pricing adjustments.

Bio-Techne (TECH)-7 May 25-2025 Q3 Earnings call transcript

- **Revenue Beat**: 9% organic growth driven by biopharma (mid-teens) and GMP reagents (+90% YoY).
- **AI Innovation**: 4 new designer proteins launched, targeting cell therapy applications with enhanced functionality.
- **China Recovery**: Q3 expected to shift to modest growth as stimulus and pharma funding materialize.
- **Instrument Growth**: Protein analysis instruments up low single digits, with 8/9 quarters of double-digit consumable growth.
- **Margin Expansion**: Operating margin improved 110bps QoQ to 30.1%, with further upside in second half despite FX headwinds.
- **M&A Focus**: Strategic acquisitions planned for cell therapy and protein analysis tools, supported by strong cash position.


**【CEO Summary Section】**
- **Q2 Organic Revenue Growth**: 9% driven by biopharma (mid-teens) and EMEA (low double digits), with GMP reagents up 90% YoY.
- **GMP Reagents Momentum**: TTM revenue growth of 40%, with 500+ customers (85 in clinical trials, 6 in Phase III).
- **AI-Engineered Proteins**: 4 new designer proteins launched, targeting cell therapy applications with enhanced stability and activity.
- **China Recovery**: Q2 sales down low single digits, expected to shift to modest growth in Q3 due to stimulus and funding improvements.
- **Instrument Growth**: Protein analysis instruments grew low single digits (mid-single excluding China), with 8/9 quarters of double-digit consumable growth.

**【CFO Financial Commentary】**
- **Q2 Financial Highlights**: 
  - Adjusted EPS: $0.42 (vs. $0.40 YoY), GAAP EPS: $0.22.
  - Revenue: $297M (+9% YoY), Protein Sciences: $211.6M (+8% organic), Diagnostics & Spatial: $84.1M (+12% YoY).
  - Gross Margin: 70.5% (vs. 69.7% YoY), Operating Margin: 30.1% (up 110bps QoQ).
- **Cash Flow & Capital Allocation**: $84.3M cash from ops, $75.6M share buyback, $12.7M dividends. M&A remains top priority.
- **Q3 Outlook**: Upper mid-single-digit organic growth, with FX headwind of ~1%.

**【Q&A Key Takeaways】**
- **Cell Therapy Growth**: 2pts of Q2 growth from accelerated GMP orders, TTM growth of 40% despite lumpy quarterly trends.
- **China Strategy**: 2 new distribution agreements in Gulf & Turkey/Azerbaijan. Q3 modest growth expected from stimulus and pharma spending.
- **Spatial Biology**: COMET multiomic capabilities launched, with 45 new antibodies for RNA targets. Consumable pull-through expected to drive margins.
- **M&A Focus**: Prioritizing tools for cell therapy workflows and protein analysis, with strong balance sheet for strategic acquisitions.
- **Academic Market**: <1% direct NIH exposure, U.S. academic growth improving in January despite broader funding concerns.


Actual												0.3475	0.25	0.3575	0.405	0.4475	0.4675	0.4575	0.47	0.535	0.5125	0.445	0.47	0.53	0.55	0.41	0.4	0.48	0.49	0.42	0.42	0.56	0.53	0.42	0.46
Forecast												0.2875	0.1882	0.2762	0.3425	0.388	0.4253	0.4305	0.4474	0.4993	0.5191	0.4576	0.4881	0.528	0.5465	0.4347	0.4122	0.4528	0.4949	0.3816	0.3862	0.5076	0.4994	0.4214	0.434
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+20.87%	+32.84%	+29.44%	+18.25%	+15.34%	+9.92%	+6.27%	+5.05%	+7.15%	-1.27%	-2.75%	-3.71%	+0.38%	+0.64%	-5.68%	-2.96%	+6.01%	-0.99%	+10.06%	+8.75%	+10.32%	+6.13%	-0.33%	+5.99%

TECH

TECH fundamentals

TECH Q2 2026 Earnings

Earnings Call

You can ask Aime

TECH

TECH fundamentals

TECH Q2 2026 Earnings

Earnings Call

TECH Earnings Call Summary for Q2/20269:00 AM on Feb 4, 2026

TECH Earnings Call Summary for Q1/20269:00 AM on Nov 5, 2025

TECH Earnings Call Summary for Q4/20259:00 AM on Aug 6, 2025

TECH Earnings Call Summary for Q3/20259:00 AM on May 7, 2025

TECH Earnings Call Summary for Q2/20259:00 AM on Feb 5, 2025

You can ask Aime